Patients with newly diagnosed glioblastoma are now being accepted at two institutions to enter a phase 2 study to assess the efficacy of the SurVaxM vaccine in combination with standard chemotherapy.
James Radke, PhD
Advertisement
Articles by James Radke, PhD
Advertisement
Latest Updated Articles
Phase 2 Study of Novel Vaccine Underway in Newly Diagnosed GlioblastomaPublished: September 15th 2015 | Updated:
Advertisement
Advertisement
